How many drugs treat Female hypogonadism syndrome?

Drug Landscape tracks 9 marketed treatments for Female hypogonadism syndrome (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Female hypogonadism syndrome?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/female-hypogonadism-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Female hypogonadism syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Female hypogonadism syndrome (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Female hypogonadism syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Depoestradiol	ESTRADIOL CYPIONATE	Pfizer	Estrogen	Estrogen receptor beta	1979-01-01
Ogen .625	estrone sulphate	Pfizer	estropipate	Steryl-sulfatase	1977-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Micronor	norethisterone	Johnson & Johnson	Progestin	GnRH receptors	1962-01-01
Noretynodrel	NORETHYNODREL	Pfizer	norethynodrel	Progesterone receptor	1961-01-01
Delestrogen	ESTRADIOL VALERATE	Ph Health	Estrogen	Estrogen receptor	1954-01-01
Amchafibrin	Amchafibrin	Fundación Pública Andaluza Progreso y Salud		Plasminogen
transamin	transamin	Erzincan Military Hospital		Plasminogen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Female hypogonadism syndrome
Erzincan Military Hospital · 1 drug in Female hypogonadism syndrome
Exela Pharma · 1 drug in Female hypogonadism syndrome
Fundación Pública Andaluza Progreso y Salud · 1 drug in Female hypogonadism syndrome
Johnson & Johnson · 1 drug in Female hypogonadism syndrome
Pfizer Inc. · 1 drug in Female hypogonadism syndrome
· 1 drug in Female hypogonadism syndrome
Ph Health · 1 drug in Female hypogonadism syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Female hypogonadism syndrome:

Cite this brief

Drug Landscape (2026). Female hypogonadism syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/female-hypogonadism-syndrome. Accessed 2026-06-10.

Female hypogonadism syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing